Combination therapies of egfr inhibitors

2:

• A method of treating a cancer in a subject, comprising administering to the subject a combination according to claim 1.

3-18. (canceled)

19:

• The method of claim 2, wherein the cancer is a solid tumor, a soft tissue tumor (e.g., a hematological cancer, leukemia, lymphoma, or myeloma), and a metastatic lesion of any of the aforesaid cancers.

20-23. (canceled)

24:

• The method of claim 2, wherein the nivolumab is administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg., e.g., once a week to once every 2, 3, or 4 weeks.

25:

• The method of claim 2, wherein the nivolumab is administered at a dose from about 10 to 20 mg/kg every other week.

26:

• The method of claim 2, wherein the nivolumab, is administered intravenously at a dose from about 1 mg/kg to 3 mg/kg, e.g., about 1 mg/kg, 2 mg/kg or 3 mg/kg, every two weeks.

The method of claim 2, wherein the nivolumab, is administered by injection at a dose of 3 mg/kg every two weeks.

The method of claim 2, wherein the nivolumab, is administered intravenously at a dose of about 2 mg/kg at 3-week intervals.

The method of claim 2, wherein the cancer is EGFR mutated non-small cell lung cancer.

(canceled)

The method of claim 2, wherein the compound of formula I is administered at an oral dose of about 50 to 500 mg, e.g., about 100 mg to 400 mg, about 150 mg to 350 mg, or about 200 mg to 300 mg, e.g., about 100 mg, 150 mg or 200 mg;

• every other day, daily, twice or three times a day.

31:

• The method of claim 2, wherein the cancer is EGFR-mutant NSCLC in patients progressing on erlotinib or gefitinib.

32:

• The method of claim 2, wherein the compound of formula I is administered 150 mg qd on a continuous daily dose for compound of formula I or wherein the compound of formula I is administered prior to nivolumab.